All data are based on the daily closing price as of May 12, 2026
l

Lunit

328130.KQ
11.83 USD
-1.13
-8.72%

Overview

Last close
11.83 usd
Market cap
879.60M usd
52 week high
58.23 usd
52 week low
11.83 usd
Target price
10.06 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
16.124
Price/Book Value
10.7001
Enterprise Value
1.05B usd
EV/Revenue
18.7809
EV/EBITDA
-45.3273

Key financials

Revenue TTM
55.76M usd
Gross Profit TTM
55.76M usd
EBITDA TTM
-48.83M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
256.40M usd
Net debt
54.94M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
  • Symbol
    328130.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Health Information Services
  • CEO
    Mr. Beomseok Brandon Suh
  • Headquarter
    Seoul
  • Web site
    https://www.lunit.io
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top